Tirzepatide’s Glowing Obesity Data Steal Show On Lilly’s Earnings Call

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Tirzepatide shows ability to produce a mean 52-pound weight loss at 72 weeks, setting up a market showdown with Novo’s Wegovy. Lilly’s quarterly call included reassurance about donanemab for Alzheimer’s and high growth for its COVID-19 antibody.

Head to head battle
Tirzepatide data in obesity may set up head-to-head battle between Lilly, Novo Nordisk • Source: Alamy

The focus of Eli Lilly and Company’s first quarter earnings report was on new Phase III data for tirzepatide in obesity that set its cardiometabolic business up for future success. Multiple analysts said the better-than-expected data position the GLP-1/GIP analog as a strong competitor to Novo Nordisk A/S’s Wegovy (semaglutide 2.4mg) in the weight loss market and open the possibility of Lilly filing for approval earlier than 2024, the current projection.

In a release issued in tandem with its quarterly earnings results on 28 April, Lilly noted that tirzepatide – which...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.